However, a meta-analysis of the literature between 1996 and 2009 found an increased relative risk for death due to Pca or biochemical (prostate-specific antigen, PSA) recurrence of the disease in patients with moderate to high levels of tumour ErbB2 expression [11]. The gene discussed is KLK3; the disease is posterior cortical atrophy.